108 related articles for article (PubMed ID: 32173649)
1. Effect of Osimertinib on the expression of serum mmp-7 and mmp-9 in patients with non-small cell lung cancer.
Yang N; Wan R; Dai L; Wang Y; Tan X; Chen M; Guo J; Zhou H
Pak J Pharm Sci; 2020 Jan; 33(1(Special)):499-504. PubMed ID: 32173649
[TBL] [Abstract][Full Text] [Related]
2. Analysis of efficacy and prognosis of Osimertinib combined with docetaxel for non-small cell lung cancer.
Huang Y; Shi Y; Yin X; Zhang Q
J BUON; 2020; 25(2):805-810. PubMed ID: 32521871
[TBL] [Abstract][Full Text] [Related]
3. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
Odogwu L; Mathieu L; Goldberg KB; Blumenthal GM; Larkins E; Fiero MH; Rodriguez L; Bijwaard K; Lee EY; Philip R; Fan I; Donoghue M; Keegan P; McKee A; Pazdur R
Oncologist; 2018 Mar; 23(3):353-359. PubMed ID: 29242281
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.
Yi L; Fan J; Qian R; Luo P; Zhang J
Int J Cancer; 2019 Jul; 145(1):284-294. PubMed ID: 30613959
[TBL] [Abstract][Full Text] [Related]
5. Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial.
Nakao A; Hiranuma O; Uchino J; Sakaguchi C; Kita T; Hiraoka N; Ishizuka T; Kubota Y; Kawasaki M; Goto Y; Imai H; Hattori N; Nakatomi K; Uramoto H; Uryu K; Fukuda M; Uchida Y; Yokoyama T; Akai M; Mio T; Nagashima S; Chihara Y; Tamiya N; Kaneko Y; Mouri T; Yamada T; Yoshimura K; Fujita M; Takayama K
Oncologist; 2019 May; 24(5):593-e170. PubMed ID: 30651400
[TBL] [Abstract][Full Text] [Related]
6. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I
Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328
[TBL] [Abstract][Full Text] [Related]
7. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P
Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353
[TBL] [Abstract][Full Text] [Related]
8. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
[TBL] [Abstract][Full Text] [Related]
9. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for
Tsuboi M; Weder W; Escriu C; Blakely C; He J; Dacic S; Yatabe Y; Zeng L; Walding A; Chaft JE
Future Oncol; 2021 Nov; 17(31):4045-4055. PubMed ID: 34278827
[TBL] [Abstract][Full Text] [Related]
11. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.
Mehlman C; Cadranel J; Rousseau-Bussac G; Lacave R; Pujals A; Girard N; Callens C; Gounant V; Théou-Anton N; Friard S; Trédaniel J; Blons H; Dujon C; Duchemann B; Schischmanoff PO; Chinet T; Giroux Leprieur E
Lung Cancer; 2019 Nov; 137():149-156. PubMed ID: 31600593
[TBL] [Abstract][Full Text] [Related]
12. Early-onset interstitial pneumonitis in a patient with advanced non-small cell lung cancer treated with crizotinib and osimertinib.
Cheng Y; Yu Q; Xiong Y; Guo C; Nie L
Thorac Cancer; 2021 Mar; 12(5):690-692. PubMed ID: 33438350
[TBL] [Abstract][Full Text] [Related]
13. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.
Nakashima K; Kimura M; Akamatsu H; Daga H; Imai H; Taira T; Ko R; Hisamatsu Y; Nishino K; Sugimoto T; Miyashita Y; Takahashi T;
Jpn J Clin Oncol; 2019 Jul; 49(7):671-675. PubMed ID: 30920616
[TBL] [Abstract][Full Text] [Related]
14. Drug-Induced Kidney Injury Caused by Osimertinib: Report of a Rare Case.
Niitsu T; Hayashi T; Uchida J; Yanase T; Tanaka S; Kuroyama M; Ueno K
Nephron; 2022; 146(1):58-63. PubMed ID: 34569520
[TBL] [Abstract][Full Text] [Related]
15. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K
Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.
Leighl NB; Karaseva N; Nakagawa K; Cho BC; Gray JE; Hovey T; Walding A; Rydén A; Novello S
Eur J Cancer; 2020 Jan; 125():49-57. PubMed ID: 31838405
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study.
Wang X; Cai J; Zeng Z; Liu A
BMC Cancer; 2021 Jul; 21(1):873. PubMed ID: 34330231
[TBL] [Abstract][Full Text] [Related]
18. Osimertinib (Tagrisso) for adjuvant treatment of NSCLC.
Med Lett Drugs Ther; 2023 Aug; 65(1682):e131-e132. PubMed ID: 37516900
[No Abstract] [Full Text] [Related]
19. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.
Provencio M; Terrasa J; Garrido P; Campelo RG; Aparisi F; Diz P; Aguiar D; García-Giron C; Hidalgo J; Aguado C; González JG; Esteban E; Gómez-Aldavarí L; Moran T; Juan O; Chara LE; Marti JL; Castro RL; Ortega AL; Moreno EM; Coves J; Sánchez Peña AM; Bosch-Barrera J; Gastaldo AS; Núñez NF; Del Barco E; Cobo M; Isla D; Majem M; Navarro F; Calvo V
BMC Cancer; 2021 Mar; 21(1):230. PubMed ID: 33676426
[TBL] [Abstract][Full Text] [Related]
20. Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan.
Ohe Y; Kato T; Sakai F; Kusumoto M; Endo M; Saito Y; Baba T; Sata M; Yamaguchi O; Sakamoto K; Sugeno M; Tamura R; Tokimoto T; Shimizu W; Gemma A
Jpn J Clin Oncol; 2020 Aug; 50(8):909-919. PubMed ID: 32548617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
